A newly published study in Molecular Cell highlights an exciting advance in topoisomerase biology and potential cancer therapeutics. Importantly, this work was enabled using topoisomerase reagents and assay technologies supplied by TopoGEN.

Konada and colleagues report that Heat Shock Factor 1 (HSF1) selectively stimulates the catalytic activity of DNA topoisomerase IIβ (TOP2β) while exerting minimal effects on the closely related TOP2α isoform. The authors demonstrate that HSF1 physically associates with TOP2β, enhances its DNA cleavage and relaxation activities, and promotes TOP2β engagement with chromatin. In contrast, TOP2α is largely unaffected.

These findings are especially significant because TOP2 poisons such as etoposide and doxorubicin remain among the most important anti-cancer agents in clinical oncology. While these drugs effectively kill rapidly dividing cancer cells, they also produce serious long-term toxicities. Increasing evidence suggests that many of these adverse effects—including cardiotoxicity and therapy-related secondary malignancies—are mediated primarily through TOP2β rather than TOP2α.

The study further demonstrates that HSF1 inhibitors reduce TOP2β activity and protect post-mitotic cells from TOP2 poison-induced damage while preserving anti-tumor activity in proliferating cells. This raises the intriguing possibility that selective modulation of the HSF1–TOP2β axis could someday be used to reduce the cardiac and neurological side effects associated with topoisomerase-targeted chemotherapy without compromising therapeutic efficacy.

For the topoisomerase field, this work provides a new mechanistic framework for understanding isoform-selective regulation and opens the door to strategies that may separate anti-cancer activity from dose-limiting toxicity. TopoGEN is proud that its reagents and expertise continue to support groundbreaking discoveries that advance both fundamental biology and translational medicine.